Trials / Completed
CompletedNCT02189577
Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients
A Multinational, Multicentre, Randomised, Double Blind, Placebo-Controlled, 2-way Crossover Study to Evaluate the Efficacy and Safety of Glycopyrrolate Bromide Administered Via pMDI (CHF 5259), for the Treatment of Patients With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of CHF 5259 (glycopyrrolate bromide) for the treatment of COPD patients.
Detailed description
A Multinational, Multicentre, Randomised, Double Blind, Placebo-Controlled, 2-way Crossover Study to Evaluate the Efficacy and Safety of Glycopyrrolate Bromide Administered Via pMDI (CHF 5259), for the Treatment of Patients With Chronic Obstructive Pulmonary Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHF 5259 | Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design. |
| DRUG | Placebo | Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design. |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2014-07-14
- Last updated
- 2021-10-29
Locations
29 sites across 4 countries: Bulgaria, Germany, Poland, United Kingdom
Source: ClinicalTrials.gov record NCT02189577. Inclusion in this directory is not an endorsement.